A Phase 1/2 interventional study of KRRO-110 in Alpha-1 Anti-trypsin Deficiency and AATD, sponsored by Korro Bio, Inc.. Terminated at 5 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Korro Bio, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia — 7 open to participants now, 8 under way, 2 of them phase 3. alpha 1-Antitrypsin Deficiency · Australia.
Among the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, this one is the 14th largest by enrollment, is the only one that started in 2025, is one of 5 in phase 1/2, and was the 15th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →7 of the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia are open now. Recruiting first, the newest first:
CRISPR Therapeutics · Sites in Australia
Ages 18–75
Tessera Therapeutics, Inc. · Sites in Australia, United States, Netherlands and 2 more countries
Ages 18–70
AIRNA Corporation · Sites in Australia, Georgia, Germany and 6 more countries
Ages 18–74
Wave Life Sciences USA, Inc. · Sites in Australia, Canada, Finland and 3 more countries
Ages 18–70
Beam Therapeutics Inc. · Sites in Australia, United States, Ireland and 3 more countries
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is above the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 70 across the 18 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 10 most frequent:
Korro Bio, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Korro Bio, Inc. has 1 study filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
1 of the studies in alpha 1-Antitrypsin Deficiency with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06405633Wave Life Sciences USA, Inc.A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).
Inclusion Criteria:
Part A SAD cohort Inclusion Criteria (Healthy Volunteers)
PiZZ Genotype (Part A SAD and Part B MAD cohorts) Inclusion Criteria (PiZZ Genotype)
Exclusion Criteria:
Exclusion Criteria (Healthy Volunteers)
Exclusion Criteria (PiZZ Genotype)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle (LNP) administered by intravenous (IV) infusion as a single dose in Part A (SAD), multi-dose in Part B (MAD).
Drug: KRRO-110
Placebo, IV administration
Drug: KRRO-110
KRRO-110 drug product, IV
Safety and Tolerability
Type, frequency, and severity of treatment-emergent adverse events (TEAEs)
Time frame: From Day 1 to Day 43 in the SAD and from Day 1 to Day 85 in the MAD
Pharmacokinetics (PK) of KRRO-110
PK profile of KRRO-110 including maximum blood concentration (Cmax)
Time frame: Day 1 to Day 43 (SAD), and Day 1 to Day 85 (MAD)
Pharmacodynamics (PD) of KRRO-110
PD profile of KRRO-110 based on change from Baseline in alpha-antitrypsin (AAT) enzyme levels at all measured timepoints (PiZZ participants only).
Time frame: Day 1 to Day 43 (SAD), and Day 1 to Day 85 (MAD)
Pharmacokinetics (PK) of KRRO-110
PK profile of KRRO-110 half-life (t1/2), area under the concentration-time curve (AUC), and trough level (MAD cohorts only).
Time frame: Day 1 to Day 43 (SAD), and Day 1 to Day 85 (MAD)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Oct 2025, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
alpha 1-Antitrypsin Deficiency →
Korro Bio, Inc.